Rallybio reports positive data in its clinical program for the prevention of fetal and neonatal alloimuune thrombocytopenia (FNAIT) January 6, 2022 News, Rallybio Rallybio today announced data from its ongoing Phase 1/2 study of RLYB211 showing significant benefit over placebo. Continue Reading Share This Twitter Facebook LinkedIn Email